Literature DB >> 25868415

Analysis of cyst size and tumor markers in the management of pancreatic cysts: support for the original Sendai criteria.

Rebecca L Hoffman1, Jenna L Gates2, Michael L Kochman3, Gregory G Ginsberg3, Nuzhat A Ahmad3, Vinay Chandrasekhara3, Emma E Furth4, Charles M Vollmer2, Jeffrey A Drebin2.   

Abstract

BACKGROUND: In 2006, the Sendai Consensus Guidelines identified size >3.0 cm as the only independent predictor of malignancy in incidentally discovered pancreatic cysts. The 2012 updated guidelines increased emphasis on radiographic features over size. Earlier studies included patients with preoperatively diagnosed carcinoma or with a corresponding mass. In this report, we characterize the use of size and serum tumor markers in the initial evaluation of pancreatic cystic neoplasms without preoperatively diagnosed adenocarcinoma and correlate them with clinical and pathologic outcomes. STUDY
DESIGN: A retrospective cohort study was undertaken of 112 patients with a resected pancreatic cystic neoplasm. Patient demographics, cyst characteristics, preoperative serum tumor markers, morbidity, and mortality were captured. Statistical analysis included nonparametric tests of comparison, multivariate logistic regression, and receiver operating characteristic curve analyses.
RESULTS: One hundred and twelve pancreatic cystic neoplasms were resected; there was one perioperative death. Mucinous cysts were common (78%), followed by serous cysts (13%). In total, 17% of cysts harbored malignancy. On multivariate analysis, the risk of malignancy in cysts≥3 cm was more than 4 times that of smaller cysts (relative risk (RR)=4.32; 95% CI, 1.55-12.07). There was no significant difference in serum CEA, cancer antigen 19-9, or cyst-fluid CEA levels between the benign and malignant groups. At a median follow-up of 30 months, the incidence of diabetes was 15%.
CONCLUSIONS: Surgical resection of pancreatic cysts can be performed with low perioperative mortality and acceptable long-term morbidity. Use of cyst size as a rationale for resection of cystic lesion, as per the Sendai criteria, is justified.
Copyright © 2015 American College of Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25868415     DOI: 10.1016/j.jamcollsurg.2015.02.013

Source DB:  PubMed          Journal:  J Am Coll Surg        ISSN: 1072-7515            Impact factor:   6.113


  4 in total

1.  Long-Term Assessment of Pancreatic Function After Pancreatectomy for Cystic Neoplasms.

Authors:  Kevin P Shah; Katherine A Baugh; Lisa S Brubaker; George Van Buren; Nicole Villafane-Ferriol; Amy L McElhany; Sadde Mohamed; Eric J Silberfein; Cary Hsu; Nader N Massarweh; Hop S Tran Cao; Jose E Mendez-Reyes; William E Fisher
Journal:  J Surg Res       Date:  2019-11-15       Impact factor: 2.192

Review 2.  Elevating pancreatic cystic lesion stratification: Current and future pancreatic cancer biomarker(s).

Authors:  Joseph Carmicheal; Asish Patel; Vipin Dalal; Pranita Atri; Amaninder S Dhaliwal; Uwe A Wittel; Mokenge P Malafa; Geoffrey Talmon; Benjamin J Swanson; Shailender Singh; Maneesh Jain; Sukhwinder Kaur; Surinder K Batra
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2019-10-30       Impact factor: 10.680

3.  Incidental, Small (< 3 cm), Unilocular, Pancreatic Cysts: Factors That Predict Lesion Progression during Imaging Surveillance.

Authors:  Go Eun Kim; Sang Soo Shin; Jin Woong Kim; Suk Hee Heo; Hyo Soon Lim; Chung Hwan Jun; Yong Yeon Jeong
Journal:  Korean J Radiol       Date:  2017-09-21       Impact factor: 3.500

4.  The value of systemic inflammatory markers in identifying malignancy in mucinous pancreatic cystic neoplasms.

Authors:  Wentao Zhou; Yefei Rong; Tiantao Kuang; Yadong Xu; Xiaojing Shen; Yuan Ji; Wenhui Lou; Dansong Wang
Journal:  Oncotarget       Date:  2017-12-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.